{
  "name": "Geroscience and Longevity Clinical Trials Comparison",
  "description": "Comparative protocol parameters, intervention designs, sample sizes, and endpoint structures across landmark human geroscience and metabolic longevity clinical trials, compiled from published trial protocols, ClinicalTrials.gov registries, and peer-reviewed outcomes literature.",
  "page": "https://casrai.org/guides/tame-trial",
  "publisher": "CASRAI",
  "license": "https://creativecommons.org/licenses/by/4.0/",
  "dateModified": "2026-11-20T19:44:16Z",
  "temporalCoverage": "2015-2026",
  "spatialCoverage": "United States",
  "columns": [
    {
      "name": "Trial Acronym",
      "unit": "",
      "description": "Abbreviated study protocol identifier"
    },
    {
      "name": "Intervention Molecule",
      "unit": "",
      "description": "Primary pharmacological or dietary intervention tested"
    },
    {
      "name": "Target Population",
      "unit": "",
      "description": "Key cohort demographic and baseline inclusion criteria"
    },
    {
      "name": "Sample Size",
      "unit": "participants",
      "description": "Target or enrolled participant count"
    },
    {
      "name": "Primary Endpoint Type",
      "unit": "",
      "description": "Design category of primary outcome measure"
    },
    {
      "name": "Follow-Up Duration",
      "unit": "years",
      "description": "Planned or extended longitudinal study duration"
    },
    {
      "name": "Regulatory Precedent",
      "unit": "",
      "description": "Regulatory indication model or trial objective"
    }
  ],
  "rows": [
    {
      "Trial Acronym": "TAME",
      "Intervention Molecule": "Metformin extended-release (1500 mg/day)",
      "Target Population": "Older adults aged 65-79 without diabetes",
      "Sample Size": 3000,
      "Primary Endpoint Type": "Composite multi-morbidity event delay",
      "Follow-Up Duration": 6,
      "Regulatory Precedent": "Multi-morbidity indication framework"
    },
    {
      "Trial Acronym": "MILES",
      "Intervention Molecule": "Metformin (1700 mg/day)",
      "Target Population": "Older adults aged 65-90 with impaired glucose tolerance",
      "Sample Size": 14,
      "Primary Endpoint Type": "Adipose and muscle tissue transcriptomic pathways",
      "Follow-Up Duration": 0.5,
      "Regulatory Precedent": "Biological aging mechanism exploration"
    },
    {
      "Trial Acronym": "DPPOS",
      "Intervention Molecule": "Metformin (1700 mg/day) vs. Lifestyle",
      "Target Population": "Prediabetic cohort followed longitudinally",
      "Sample Size": 3234,
      "Primary Endpoint Type": "Diabetes incidence and microvascular complications",
      "Follow-Up Duration": 20,
      "Regulatory Precedent": "Diabetes prevention and long-term safety profile"
    },
    {
      "Trial Acronym": "CALERIE",
      "Intervention Molecule": "25% Caloric Restriction",
      "Target Population": "Healthy non-obese adults aged 21-50",
      "Sample Size": 218,
      "Primary Endpoint Type": "Resting metabolic rate and core body temperature",
      "Follow-Up Duration": 2,
      "Regulatory Precedent": "Physiological aging biomarkers in non-obese humans"
    }
  ],
  "sources": [
    {
      "title": "Cell Metabolism: Metformin as a Tool to Target Aging",
      "url": "https://pubmed.ncbi.nlm.nih.gov/27304507/",
      "accessed": "2026-11-20"
    },
    {
      "title": "ClinicalTrials.gov: Metformin in Longevity Study (MILES)",
      "url": "https://clinicaltrials.gov/study/NCT02432287",
      "accessed": "2026-11-20"
    },
    {
      "title": "The Lancet Diabetes and Endocrinology: DPPOS 15-Year Follow-up",
      "url": "https://pubmed.ncbi.nlm.nih.gov/26377054/",
      "accessed": "2026-11-20"
    },
    {
      "title": "American Federation for Aging Research: TAME Leadership News",
      "url": "https://www.afar.org/news/board-members-in-the-news-nir-barzilai-and-david-sinclair-on-the-science-behind-the-longevity-movement-in-vogue",
      "accessed": "2026-11-20"
    }
  ]
}